x

Science

Rockefeller Advances Trial of COVID-19 Antibody Drug and Other Pandemic-Related Research

February 12, 2021

NEW YORK — The Rockefeller University in New York has begun human trials of a new COVID-19 antibody drug that, if administered early, could prevent people who have been infected from developing severe cases of the disease.

Development of the drug took place alongside a raft of other COVID-19 research initiatives at the university that have yielded useful knowledge and developments.

The new treatment tool promises to “stop the virus in its tracks,” according to Michel C. Nussenzweig, who led the project alongside researchers including Theodora Hatziioannou and Charles M. Rice, recent recipient of a Nobel Prize. Other Rockefeller research indicates that immunity from reinfection with COVID-19 might last six months, explores why the disease can lead to such devastating complications, suggests that the new virus variants may require updates to the vaccines, and uses lab-made “micro-lungs” to model how the disease affects the human body.

In April 2020, the Stavros Niarchos Foundation (SNF) made a $3 million grant as part of its $100 million global COVID-19 relief initiative to support research related to COVID-19 at the university.

RELATED

Climate change added at least 10% more rain to Hurricane Ian, a study prepared immediately after the storm shows.

Top Stories

Columnists

A pregnant woman was driving in the HOV lane near Dallas.

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.

Video

After Amazon, Google’s First Cloud Region Coming to Greece

ATHENS - Despite having a costly Internet that’s the slowest in the European Union, Greece is continuing to attract high-tech giants, with Alphabet’s Google planning to create its first cloud region in the country.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. abc@xyz.com

You may unsubscribe at any time using the link in our newsletter.